SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Genome-based Drug Discovery

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2109026

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2109026

Bioinformatics Market by Offering [Software (Genomics, Multiomics, Proteomics), Services (Analysis, Sequencing)], Function (Variant & Structural Analysis), Use Case (Drug Discovery, Biomarker), End User (Pharma & Biotech, CROs) - Global Forecast to 2031

PUBLISHED:
PAGES: 488 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global bioinformatics market is projected to reach USD 34.41 billion by 2031, up from USD 18.63 billion in 2026, at a CAGR of 13.1% over the forecast period. Rapid growth in genomics research, precision medicine initiatives, and drug discovery programs has significantly increased demand for bioinformatics platforms that store, manage, analyze, and interpret complex biological datasets.

Scope of the Report
Years Considered for the Study2024-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD MN/BN)
SegmentsOffering, Function, Use Case, End User
Regions coveredNorth America, Asia Pacific, Europe, South America, Middle East & Africa

Pharmaceutical and biotechnology companies, academic institutions, and healthcare organizations are increasingly adopting integrated bioinformatics solutions to accelerate research, improve clinical decision-making, and optimize therapeutic development. Furthermore, the growing digital transformation of life science research, coupled with rising investments in computational biology and cloud-based bioinformatics platforms, is improving workflow efficiency, enabling large-scale data sharing, and supporting collaborative research across organizations.

Bioinformatics Market - IMG1

"End-to-end solutions projected to be the largest software segment in the bioinformatics market"

Software-based end-to-end solutions are expected to dominate market share during the forecast period. This dominance is driven by growing demand for integrated platforms that support complete bioinformatics workflows, including biological data acquisition, storage, processing, analysis, visualization, interpretation, and reporting. These comprehensive solutions enable researchers and clinicians to efficiently manage complex genomic, proteomic, transcriptomic, and multi-omics datasets through a single platform, reducing workflow complexity and improving operational efficiency. As the volume and complexity of biological data continue to increase, demand for scalable, integrated bioinformatics platforms is expected to further strengthen the leadership of the end-to-end solutions segment throughout the forecast period.

"By sector, medical biotechnology accounted for the major share of the bioinformatics market"

Within the sector, medical biotechnology accounted for the largest share, driven by the growing use of bioinformatics across genomics, precision medicine, molecular diagnostics, drug discovery, biomarker identification, and clinical research. The rising prevalence of chronic diseases, cancer, and rare genetic disorders has further accelerated the adoption of bioinformatics solutions to support personalized treatment strategies and advanced molecular diagnostics. In addition, ongoing advances in next-generation sequencing (NGS), artificial intelligence (AI), machine learning, and cloud-based bioinformatics platforms have improved the speed, scalability, and accuracy of biological data analysis. Increasing investments in life science research, precision medicine initiatives, and genomic medicine programs are expected to further reinforce the medical biotechnology segment's leading position throughout the forecast period.

"Asia Pacific to witness the fastest growth rate during the forecast period."

The bioinformatics market in Asia Pacific is projected to have the highest CAGR during the forecast period, primarily driven by rising investments in genomics research, precision medicine, and biotechnology across emerging economies such as China, India, Japan, South Korea, and Singapore. Governments in the region are actively supporting genomics and life sciences research through funding initiatives, national genomics programs, and policies that promote digital healthcare and biotechnology innovation.

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 46%, Tier 2: 34%, and Tier 3: 20%
  • By Designation - C-level: 35%, Director-level: 25%, and Others: 40%
  • By Region - North America: 45%, Europe: 30%, Asia Pacific: 20%, Latin America: 3%, and Middle East & Africa: 2%.

Thermo Fisher Scientific Inc. (US) & Illumina, Inc. (US) are some of the key players in the bioinformatics market

  • The study includes an in-depth competitive analysis of these key players in the bioinformatics market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the bioinformatics market by offerings (software & bioinformatics services), by function (data analysis, structural & functional analysis, multi-omics integration, clinical interpretation, data visualization & reporting, other functions), by use case (drug discovery & development, precision medicine, clinical diagnostics, biomarker discovery, research & academic applications, other use cases), by sector (medical biotechnology, animal biotechnology, plant biotechnology, environmental biotechnology, forensic biotechnology, other sectors), by end user (pharmaceutical & biotechnology companies, academic and research institutes, hospitals & clinical diagnostic laboratories, contract research organizations (CROs) & contract development and manufacturing organizations (CDMOs), government and public health organizations, other end users), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa). The scope of the report covers detailed information on the major factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the bioinformatics market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, partnerships, agreements, product and service launches, mergers and acquisitions, and recent developments associated with the bioinformatics market. The report also covers a competitive analysis of upcoming startups in the bioinformatics market ecosystem.

Reasons to buy this report

The report will provide market leaders and new entrants with the closest approximations of revenue figures for the bioinformatics market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to position their businesses more effectively and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:

  • Analysis of key drivers (increasing adoption of next-generation sequencing (NGS), growing demand for personalized medicine, rising pharmaceutical and biotechnology R&D expenditure, increasing public and private-sector funding for bioinformatics, increasing adoption of AI and machine learning in the life sciences), restraints (high cost of bioinformatics infrastructure, data privacy, security, and regulatory compliance concerns, shortage of skilled bioinformatics professionals), opportunities (lucrative opportunities in emerging markets, expansion of clinical bioinformatics, adoption of cloud and federated bioinformatics platforms, growth of bioinformatics outsourcing services), and challenges (management of large data volumes, lack of interoperability and multiplatform capabilities, growing competition from in-house development and publicly available tools, integration of multi-omics datasets)
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the bioinformatics market
  • Market Development: Comprehensive information about lucrative markets - the report analyzes the bioinformatics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioinformatics market
  • Competitive Assessment: In-depth assessment of market share, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), among others, in the bioinformatics market.
Show more
Product Code: HIT 7543

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 BIOINFORMATICS MARKET OVERVIEW
  • 3.2 BIOINFORMATICS MARKET, BY OFFERING & REGION
  • 3.3 BIOINFORMATICS MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Increasing adoption of next-generation sequencing (NGS)
      • 4.2.1.2 Growing demand for personalized medicine
      • 4.2.1.3 Increasing pharmaceutical and biotechnology R&D expenditure
      • 4.2.1.4 Increasing public and private-sector funding for bioinformatics
      • 4.2.1.5 Increasing adoption of AI and machine learning in life sciences
      • 4.2.1.6 Decreasing cost of genome sequencing
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High cost of bioinformatics infrastructure
      • 4.2.2.2 Data privacy, security, and regulatory compliance concerns
      • 4.2.2.3 Shortage of skilled bioinformatics professionals
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Lucrative opportunities in emerging markets
      • 4.2.3.2 Expansion of clinical bioinformatics
      • 4.2.3.3 Adoption of cloud and federated bioinformatics platforms
      • 4.2.3.4 Growth of bioinformatics outsourcing services
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Management of large data volumes
      • 4.2.4.2 Lack of interoperability and multiplatform capabilities
      • 4.2.4.3 Growing competition from in-house development and publicly available tools
      • 4.2.4.4 Integration of multiomics datasets
  • 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF SUPPLIERS
    • 5.1.4 BARGAINING POWER OF BUYERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
    • 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
    • 5.3.1 RESEARCH & PRODUCT DEVELOPMENT
    • 5.3.2 TECHNOLOGY INFRASTRUCTURE
    • 5.3.3 PLATFORM DEVELOPMENT
    • 5.3.4 DISTRIBUTION
    • 5.3.5 MARKETING & SALES
    • 5.3.6 POST-SALE SERVICES
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 INDICATIVE PRICING FOR BIOINFORMATICS MARKET, BY OFFERING (2025)
    • 5.5.2 INDICATIVE PRICING IN BIOINFORMATICS MARKET, BY REGION (2025)
  • 5.6 KEY CONFERENCES AND EVENTS, 2026-2027
  • 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 CASE STUDY ANALYSIS
  • 5.10 IMPACT OF 2025 US TARIFF -BIOINFORMATICS MARKET
    • 5.10.1 INTRODUCTION
    • 5.10.2 KEY TARIFF RATES
    • 5.10.3 PRICE IMPACT ANALYSIS
    • 5.10.4 IMPACT ON COUNTRY/REGION
      • 5.10.4.1 US
      • 5.10.4.2 Europe
      • 5.10.4.3 Asia Pacific
    • 5.10.5 IMPACT ON END USERS
      • 5.10.5.1 Pharmaceutical & biotechnology companies
      • 5.10.5.2 Academic & research institutes
      • 5.10.5.3 Hospitals & clinical diagnostic laboratories
      • 5.10.5.4 Contract research organizations and contract development & manufacturing organizations
      • 5.10.5.5 Government & public health organizations

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 NEXT-GENERATION SEQUENCING TECHNOLOGIES
    • 6.1.2 ARTIFICIAL INTELLIGENCE & MACHINE LEARNING
    • 6.1.3 MULTIOMICS ANALYSIS PLATFORMS
    • 6.1.4 VARIANT INTERPRETATION & CLINICAL DECISION SUPPORT
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 GENERATIVE AI FOR BIOINFORMATICS
    • 6.2.2 AI-BASED DRUG DISCOVERY PLATFORMS
    • 6.2.3 LARGE LANGUAGE MODELS FOR LIFE SCIENCES
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 HIGH-PERFORMANCE COMPUTING
    • 6.3.2 BIG DATA ANALYTICS
    • 6.3.3 BLOCKCHAIN TECHNOLOGY
    • 6.3.4 ROBOTICS & LABORATORY AUTOMATION
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 PATENT PUBLICATION TRENDS FOR BIOINFORMATICS MARKET
    • 6.5.2 BIOINFORMATICS PATENTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 6.6 FUTURE APPLICATIONS
    • 6.6.1 AI-DRIVEN GENOMIC INTERPRETATION & CLINICAL DECISION SUPPORT
    • 6.6.2 PRECISION MEDICINE & MULTIOMICS INTEGRATION
    • 6.6.3 INTEGRATED BIOINFORMATICS FOR DRUG DISCOVERY & CLINICAL RESEARCH
  • 6.7 IMPACT OF GEN AI IN BIOINFORMATICS MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN BIOINFORMATICS MARKET
    • 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
      • 6.7.3.1 AI-powered genomics for precision medicine at Illumina and Tempus AI
    • 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 6.7.4.1 AI in bioinformatics software market
      • 6.7.4.2 Next-generation sequencing market
      • 6.7.4.3 Drug discovery market
    • 6.7.5 USERS READINESS AND IMPACT ASSESSMENT
      • 6.7.5.1 User readiness
        • 6.7.5.1.1 Pharmaceutical & biotechnology companies
        • 6.7.5.1.2 Academic & research institutes
        • 6.7.5.1.3 Hospitals & clinical diagnostic laboratories
        • 6.7.5.1.4 Contract research organizations and contract development & manufacturing organizations
      • 6.7.5.2 Impact assessment
        • 6.7.5.2.1 User A: Pharmaceutical & biotechnology companies
          • 6.7.5.2.1.1 Implementation
          • 6.7.5.2.1.2 Impact
        • 6.7.5.2.2 User B: Academic & Research Institutes
          • 6.7.5.2.2.1 Implementation
          • 6.7.5.2.2.2 Impact
        • 6.7.5.2.3 User C: Hospitals & Clinical Diagnostic Laboratories
          • 6.7.5.2.3.1 Implementation
          • 6.7.5.2.3.2 Impact
        • 6.7.5.2.4 User D: Contract research organizations and contract development & manufacturing organizations
          • 6.7.5.2.4.1 Implementation
          • 6.7.5.2.4.2 Impact

7 REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 REGULATORY FRAMEWORK
      • 7.1.2.1 North America
      • 7.1.2.2 Europe
      • 7.1.2.3 Asia Pacific
      • 7.1.2.4 Latin America
      • 7.1.2.5 Middle East & Africa
    • 7.1.3 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 INTRODUCTION
  • 8.2 DECISION-MAKING PROCESS
  • 8.3 STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.3.2 BUYING CRITERIA
  • 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.5 UNMET NEEDS FROM VARIOUS END USERS
    • 8.5.1 UNMET NEEDS
    • 8.5.2 END USER EXPECTATIONS
  • 8.6 MARKET PROFITABILITY

9 BIOINFORMATICS MARKET, BY OFFERING

  • 9.1 INTRODUCTION
  • 9.2 SOFTWARE
    • 9.2.1 NICHE POINT SOLUTIONS
      • 9.2.1.1 Increasing adoption of NGS and multiomics technologies to boost growth
    • 9.2.2 KNOWLEDGE MANAGEMENT TOOLS
      • 9.2.2.1 Rising demand for genomic variant interpretation databases
      • 9.2.2.2 Generalized knowledge management tools
        • 9.2.2.2.1 Development of novel generalized knowledge management tools to drive growth
      • 9.2.2.3 Specialized knowledge management tools
        • 9.2.2.3.1 Data security and highly reliable information storage systems to support growth
    • 9.2.3 END-TO-END SOLUTIONS
      • 9.2.3.1 Integration of artificial intelligence (AI) and machine learning (ML) to drive growth
      • 9.2.3.2 Genomic solutions
        • 9.2.3.2.1 Expansion of precision medicine and genomic diagnostics - segment driver
      • 9.2.3.3 Multiomics solutions
        • 9.2.3.3.1 Increasing integration of genomics, transcriptomics, proteomics, and metabolomics dataset to drive market
      • 9.2.3.4 Chemoinformatics solutions
        • 9.2.3.4.1 Increasing investment in R&D to boost segment
      • 9.2.3.5 Proteomics solutions
        • 9.2.3.5.1 Growing focus on protein biomarker discovery fuels adoption
      • 9.2.3.6 Transcriptomics solutions
        • 9.2.3.6.1 Rising demand for gene expression analysis accelerates adoption
      • 9.2.3.7 Metabolomics solutions
        • 9.2.3.7.1 Adoption of LC-MS and GC-MS technologies accelerates segment growth
      • 9.2.3.8 Other end-to-end Solutions
  • 9.3 SERVICES
    • 9.3.1 SEQUENCING & DATA GENERATION
      • 9.3.1.1 Increasing adoption of NGS drives demand
    • 9.3.2 DATA ANALYSIS & INTERPRETATION
      • 9.3.2.1 Growing complexity of multiomics data drives demand
    • 9.3.3 DRUG DISCOVERY & TARGET IDENTIFICATION
      • 9.3.3.1 Increasing adoption of precision medicine fuels demand
    • 9.3.4 DATABASE & DATA MANAGEMENT
      • 9.3.4.1 Exponential growth of biological data drives segment
    • 9.3.5 CLOUD & MANAGED BIOINFORMATICS
      • 9.3.5.1 Increasing adoption of cloud computing accelerates segment growth
    • 9.3.6 CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT
      • 9.3.6.1 Increasing demand for customized bioinformatics workflows boosts segment
    • 9.3.7 OTHER SERVICES

10 BIOINFORMATICS MARKET, BY FUNCTION

  • 10.1 INTRODUCTION
  • 10.2 DATA ANALYSIS
    • 10.2.1 SEQUENCE ANALYSIS
      • 10.2.1.1 Growing volume of sequencing data drives demand
    • 10.2.2 VARIANT ANALYSIS
      • 10.2.2.1 Increasing adoption of precision medicine to boost segment
    • 10.2.3 GENE EXPRESSION ANALYSIS
      • 10.2.3.1 Expanding transcriptomics research drives segment growth
    • 10.2.4 OTHER DATA ANALYSIS FUNCTIONS
  • 10.3 STRUCTURAL & FUNCTIONAL ANALYSIS
    • 10.3.1 GROWING ADOPTION OF STRUCTURE-BASED DRUG DISCOVERY AND PROTEIN MODELING TO BOOST GROWTH
  • 10.4 MULTIOMICS INTEGRATION
    • 10.4.1 INCREASING INTEGRATION OF MULTIOMICS DATA DRIVES DEMAND FOR ADVANCED BIOINFORMATICS PLATFORMS
  • 10.5 CLINICAL INTERPRETATION
    • 10.5.1 GROWING ADOPTION OF PRECISION MEDICINE AND CLINICAL GENOMICS IS PROPELS GROWTH
  • 10.6 DATA VISUALIZATION & REPORTING
    • 10.6.1 INCREASING ADOPTION OF AI-DRIVEN DRUG DISCOVERY AND COMPUTATIONAL CHEMISTRY - KEY SEGMENT DRIVER
  • 10.7 OTHER FUNCTIONS

11 BIOINFORMATICS MARKET, BY USE CASE

  • 11.1 INTRODUCTION
  • 11.2 DRUG DISCOVERY & DEVELOPMENT
    • 11.2.1 GROWING PHARMACEUTICAL R&D INVESTMENTS DRIVE GROWTH
  • 11.3 PRECISION MEDICINE
    • 11.3.1 INCREASING DEMAND FOR PERSONALIZED TREATMENT STRATEGIES TO BOOST SEGMENT
  • 11.4 CLINICAL DIAGNOSTICS
    • 11.4.1 GROWING ADOPTION OF GENOMIC TESTING - KEY DRIVER
  • 11.5 BIOMARKER DISCOVERY
    • 11.5.1 GROWING FOCUS ON PRECISION MEDICINE AND COMPANION DIAGNOSTICS TO BOOST SEGMENT
  • 11.6 RESEARCH & ACADEMIC APPLICATIONS
    • 11.6.1 INCREASING INVESTMENTS IN LIFE SCIENCE RESEARCH PROPEL SEGMENT GROWTH
  • 11.7 OTHER USE CASES

12 BIOINFORMATICS MARKET, BY SECTOR

  • 12.1 INTRODUCTION
  • 12.2 MEDICAL BIOTECHNOLOGY
    • 12.2.1 EXPANSION OF GENOMIC DIAGNOSTICS, MOLECULAR TESTING, AND PERSONALIZED HEALTHCARE TO DRIVE SEGMENT
  • 12.3 ANIMAL BIOTECHNOLOGY
    • 12.3.1 INCREASING ADOPTION OF PRECISION LIVESTOCK FARMING AND VETERINARY GENOMICS TO PROPEL GROWTH
  • 12.4 PLANT BIOTECHNOLOGY
    • 12.4.1 GROWING DEMAND FOR CLIMATE-RESILIENT AND HIGH-YIELD CROPS TO BOOST SEGMENT
  • 12.5 ENVIRONMENTAL BIOTECHNOLOGY
    • 12.5.1 INCREASING ADOPTION OF ENVIRONMENTAL DNA (EDNA) AND METAGENOMICS BOOSTS GROWTH
  • 12.6 FORENSIC BIOTECHNOLOGY
    • 12.6.1 INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING AND FORENSIC GENOMICS TO DRIVE SEGMENT
  • 12.7 OTHER SECTORS

13 BIOINFORMATICS MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 13.2.1 INCREASING PHARMACEUTICAL R&D INVESTMENTS AND ADOPTION OF ADVANCED COMPUTATIONAL TECHNOLOGIES
  • 13.3 ACADEMIC & RESEARCH INSTITUTES
    • 13.3.1 GROWING GOVERNMENT FUNDING FOR BIOMEDICAL RESEARCH DRIVES SEGMENT
  • 13.4 HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES
    • 13.4.1 INCREASED APPLICATIONS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
  • 13.5 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
    • 13.5.1 INCREASING OUTSOURCING OF DRUG DEVELOPMENT AND GROWING DEMAND FOR SPECIALIZED COMPUTATIONAL EXPERTISE
  • 13.6 GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS
    • 13.6.1 INCREASING INVESTMENTS IN GENOMIC SURVEILLANCE AND PUBLIC HEALTH INFORMATICS
  • 13.7 OTHER END USERS

14 BIOINFORMATICS MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 14.2.2 US
      • 14.2.2.1 Strong government support and rapid advances in genomics and AI drive market
    • 14.2.3 CANADA
      • 14.2.3.1 Increasing government investments in genomics and national bioinformatics infrastructure
  • 14.3 EUROPE
    • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 14.3.2 GERMANY
      • 14.3.2.1 Strong government investments in precision medicine and expanding AI-enabled bioinformatics research
    • 14.3.3 UK
      • 14.3.3.1 Strategic initiatives and funding for genomics research to support market growth
    • 14.3.4 FRANCE
      • 14.3.4.1 Market driven by national genomics programs and AI-enabled biomedical research
    • 14.3.5 ITALY
      • 14.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology
    • 14.3.6 SPAIN
      • 14.3.6.1 Growing focus on advancements in personalized medicine to support market growth
    • 14.3.7 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 14.4.2 CHINA
      • 14.4.2.1 Expansion of national genomic data infrastructure drives market
    • 14.4.3 JAPAN
      • 14.4.3.1 Rising number of collaborations in bioinformatics to drive market
    • 14.4.4 INDIA
      • 14.4.4.1 Government and private initiatives for genomics projects to propel market
    • 14.4.5 AUSTRALIA
      • 14.4.5.1 Increased genetic research to support market growth
    • 14.4.6 SOUTH KOREA
      • 14.4.6.1 National biomedical data integration and AI-driven precision medicine accelerate market
    • 14.4.7 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 14.5.2 BRAZIL
      • 14.5.2.1 Increased government investments in genomics advancements to drive market
    • 14.5.3 MEXICO
      • 14.5.3.1 Rising demand for chronic disease treatment to support growth
    • 14.5.4 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 14.6.2 GCC COUNTRIES
      • 14.6.2.1 Saudi Arabia
        • 14.6.2.1.1 Growing healthcare expenditure to boost market growth
      • 14.6.2.2 UAE
        • 14.6.2.2.1 Collaborations to advance genome sequencing and market growth
      • 14.6.2.3 Rest of GCC
    • 14.6.3 SOUTH AFRICA
      • 14.6.3.1 Growing focus on precision medicine to propel market
    • 14.6.4 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

  • 15.1 OVERVIEW
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2026
  • 15.3 REVENUE ANALYSIS, 2021-2025
  • 15.4 MARKET SHARE ANALYSIS, 2025
  • 15.5 BRAND COMPARISON
  • 15.6 COMPANY VALUATION AND FINANCIAL METRICS
  • 15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 15.7.1 STARS
    • 15.7.2 EMERGING LEADERS
    • 15.7.3 PERVASIVE PLAYERS
    • 15.7.4 PARTICIPANTS
    • 15.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 15.7.5.1 Company footprint
      • 15.7.5.2 Region footprint
      • 15.7.5.3 Offering footprint
      • 15.7.5.4 Function footprint
      • 15.7.5.5 Use case footprint
      • 15.7.5.6 End user footprint
  • 15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 15.8.1 PROGRESSIVE COMPANIES
    • 15.8.2 RESPONSIVE COMPANIES
    • 15.8.3 DYNAMIC COMPANIES
    • 15.8.4 STARTING BLOCKS
    • 15.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
      • 15.8.5.1 List of startups/SMES
      • 15.8.5.2 Competitive benchmarking of Startups/SMEs
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT LAUNCHES & ENHANCEMENTS
    • 15.9.2 DEALS
    • 15.9.3 EXPANSIONS
    • 15.9.4 OTHER DEVELOPMENTS

16 COMPANY PROFILES

  • 16.1 KEY COMPANIES
    • 16.1.1 THERMO FISHER SCIENTIFIC INC.
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products/Services offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product launches
        • 16.1.1.3.2 Deals
        • 16.1.1.3.3 Expansions
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Key strengths
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses and competitive threats
    • 16.1.2 ILLUMINA, INC.
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products/Services offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product launches
        • 16.1.2.3.2 Deals
        • 16.1.2.3.3 Expansions
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Key strengths
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses and competitive threats
    • 16.1.3 QIAGEN N.V.
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products/services offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product launches & enhancements
        • 16.1.3.3.2 Deals
        • 16.1.3.3.3 Other developments
        • 16.1.3.3.4 Expansions
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Key strengths
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses and competitive threats
    • 16.1.4 AGILENT TECHNOLOGIES, INC.
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products/Services offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Deals
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Key strengths
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses and competitive threats
    • 16.1.5 F. HOFFMANN-LA ROCHE LTD.
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products/Services offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product launches
        • 16.1.5.3.2 Deals
        • 16.1.5.3.3 Other developments
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Key strengths
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses and competitive threats
    • 16.1.6 REVVITY, INC.
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products/Services offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Product launches
        • 16.1.6.3.2 Deals
        • 16.1.6.3.3 Expansions
    • 16.1.7 EUROFINS SCIENTIFIC
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products/services offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Deals
        • 16.1.7.3.2 Expansions
    • 16.1.8 BGI GENOMICS
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products/services offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Deals
    • 16.1.9 WATERS CORPORATION
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products/services offered
    • 16.1.10 DNANEXUS, INC.
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products/services offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Product launches
        • 16.1.10.3.2 Deals
        • 16.1.10.3.3 Other developments
    • 16.1.11 OXFORD NANOPORE TECHNOLOGIES PLC
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products/Services offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Deals
        • 16.1.11.3.2 Expansions
    • 16.1.12 10X GENOMICS
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products/Services offered
      • 16.1.12.3 Recent developments
        • 16.1.12.3.1 Deals
    • 16.1.13 PACBIO
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products/Services offered
      • 16.1.13.3 Recent developments
        • 16.1.13.3.1 Product launches
        • 16.1.13.3.2 Deals
        • 16.1.13.3.3 Expansions
    • 16.1.14 SIEMENS AG
      • 16.1.14.1 Business overview
      • 16.1.14.2 Products/Services offered
      • 16.1.14.3 Recent developments
        • 16.1.14.3.1 Product launches
        • 16.1.14.3.2 Deals
        • 16.1.14.3.3 Other developments
    • 16.1.15 SOPHIA GENETICS
      • 16.1.15.1 Business overview
      • 16.1.15.2 Products/Services offered
      • 16.1.15.3 Recent developments
        • 16.1.15.3.1 Product Launches
        • 16.1.15.3.2 Deals
        • 16.1.15.3.3 Other developments
    • 16.1.16 EXCELRA
      • 16.1.16.1 Business overview
      • 16.1.16.2 Products/Services offered
      • 16.1.16.3 Recent developments
        • 16.1.16.3.1 Product Enhancement
        • 16.1.16.3.2 Deals
    • 16.1.17 GENEWIZ (AZENTA LIFE SCIENCES)
      • 16.1.17.1 Business overview
      • 16.1.17.2 Products/Services offered
      • 16.1.17.3 Recent developments
        • 16.1.17.3.1 Deals
        • 16.1.17.3.2 Other developments
    • 16.1.18 ONTOFORCE
      • 16.1.18.1 Business overview
      • 16.1.18.2 Products/Services offered
      • 16.1.18.3 Recent developments
        • 16.1.18.3.1 Product launches & enhancements
        • 16.1.18.3.2 Deals
    • 16.1.19 VELSERA INC.
      • 16.1.19.1 Business overview
      • 16.1.19.2 Products/Services offered
      • 16.1.19.3 Recent developments
        • 16.1.19.3.1 Deals
    • 16.1.20 SEQERA
      • 16.1.20.1 Business overview
      • 16.1.20.2 Products/Services offered
      • 16.1.20.3 Recent developments
        • 16.1.20.3.1 Product launches & enhancement
        • 16.1.20.3.2 Deals
        • 16.1.20.3.3 Other developments
  • 16.2 OTHER PLAYERS
    • 16.2.1 DNASTAR
    • 16.2.2 FIOS GENOMICS
    • 16.2.3 DEEP GENOMICS
    • 16.2.4 PSOMAGEN
    • 16.2.5 SOURCE BIOSCIENCE

17 RESEARCH METHODOLOGY

  • 17.1 RESEARCH APPROACH
    • 17.1.1 SECONDARY RESEARCH
      • 17.1.1.1 Key data from secondary sources
    • 17.1.2 PRIMARY RESEARCH
      • 17.1.2.1 Key data from primary sources
      • 17.1.2.2 Breakdown of primaries
      • 17.1.2.3 Insights from primary experts
  • 17.2 RESEARCH METHODOLOGY DESIGN
  • 17.3 MARKET SIZE ESTIMATION
  • 17.4 MARKET BREAKDOWN DATA TRIANGULATION
  • 17.5 MARKET SHARE ESTIMATION
  • 17.6 STUDY ASSUMPTIONS
  • 17.7 RESEARCH LIMITATIONS
    • 17.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 17.7.2 SCOPE-RELATED LIMITATIONS
  • 17.8 RISK ASSESSMENT

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS
Show more
Product Code: HIT 7543

List of Tables

  • TABLE 1 EXCHANGE RATES FOR CONVERSION TO USD
  • TABLE 2 ASIA PACIFIC: R&D INVESTMENT BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • TABLE 3 PUBLIC AND PRIVATE-SECTOR FUNDING FOR BIOINFORMATICS AND RELATED FIELDS
  • TABLE 4 BIOINFORMATICS MARKET: PORTER'S FIVE FORCES
  • TABLE 5 BIOINFORMATICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 6 INDICATIVE PRICING IN BIOINFORMATICS MARKET, BY OFFERING (2025)
  • TABLE 7 INDICATIVE PRICING OF SOFTWARE (NICHE POINT SOLUTIONS), BY REGION (2025)
  • TABLE 8 BIOINFORMATICS MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 9 CASE 1: FASTER WORKFLOWS, COST-EFFICIENCY, AND SIMPLIFIED INFRASTRUCTURE
  • TABLE 10 CASE STUDY 2: COMPREHENSIVE CLINICAL EXOME ANALYSIS TO SUPPORT DIVERSE APPLICATIONS AT HENRY FORD HEALTH
  • TABLE 11 CASE STUDY 2: CHAMPIONS ONCOLOGY SCALES MULTIOMICS ANALYSIS WITH SEQERA TO ACCELERATE CANCER THERAPY DEVELOPMENT
  • TABLE 12 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 13 COUNTRY
  • TABLE 14 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR BIOINFORMATICS MARKET
  • TABLE 15 BIOINFORMATICS MARKET: KEY PATENTS/PATENT APPLICATIONS
  • TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 REGULATORY SCENARIO IN NORTH AMERICA
  • TABLE 22 REGULATORY SCENARIO IN EUROPE
  • TABLE 23 REGULATORY SCENARIO IN ASIA PACIFIC
  • TABLE 24 REGULATORY SCENARIO IN LATIN AMERICA
  • TABLE 25 REGULATORY SCENARIO IN MIDDLE EAST & AFRICA
  • TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
  • TABLE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 28 UNMET NEEDS IN BIOINFORMATICS MARKET
  • TABLE 29 END USER EXPECTATIONS IN BIOINFORMATICS MARKET
  • TABLE 30 BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 31 BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 32 BIOINFORMATICS MARKET FOR SOFTWARE, BY REGION, 2024-2031(USD MILLION)
  • TABLE 33 NICHE POINT SOLUTIONS OFFERED BY KEY MARKET PLAYERS
  • TABLE 34 BIOINFORMATICS MARKET FOR NICHE POINT SOLUTIONS, BY REGION, 2024-2031(USD MILLION)
  • TABLE 35 BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 36 BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 37 GENERALIZED KNOWLEDGE MANAGEMENT TOOLS OFFERED BY KEY MARKET PLAYERS
  • TABLE 38 BIOINFORMATICS MARKET FOR GENERALIZED KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 39 SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS OFFERED BY KEY MARKET PLAYERS
  • TABLE 40 BIOINFORMATICS MARKET FOR SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 41 BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 42 BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 GENOMIC SOLUTIONS OFFERED BY KEY MARKET PLAYERS
  • TABLE 44 BIOINFORMATICS MARKET FOR GENOMIC SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 MULTIOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
  • TABLE 46 BIOINFORMATICS MARKET FOR MULTIOMICS SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 CHEMOINFORMATICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
  • TABLE 48 BIOINFORMATICS MARKET FOR CHEMOINFORMATICS SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 49 PROTEOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
  • TABLE 50 BIOINFORMATICS MARKET FOR PROTEOMICS SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 51 TRANSCRIPTOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
  • TABLE 52 BIOINFORMATICS MARKET FOR TRANSCRIPTOMICS SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 METABOLOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS
  • TABLE 54 BIOINFORMATICS MARKET FOR METABOLOMICS SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 OTHER END-TO-END SOLUTIONS OFFERED BY KEY MARKET PLAYERS
  • TABLE 56 BIOINFORMATICS MARKET FOR OTHER END-TO-END SOLUTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 58 BIOINFORMATICS MARKET FOR SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 59 SEQUENCING & DATA GENERATION SERVICES OFFERED BY KEY MARKET PLAYERS
  • TABLE 60 BIOINFORMATICS MARKET FOR SEQUENCING & DATA GENERATION SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 DATA ANALYSIS & INTERPRETATION SERVICES OFFERED BY KEY MARKET PLAYERS
  • TABLE 62 BIOINFORMATICS MARKET FOR DATA ANALYSIS & INTERPRETATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 63 DRUG DISCOVERY & TARGET IDENTIFICATION OFFERED BY KEY MARKET PLAYERS
  • TABLE 64 BIOINFORMATICS MARKET FOR DRUG DISCOVERY & TARGET IDENTIFICATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 65 DATABASE & DATA MANAGEMENT SERVICES OFFERED BY KEY MARKET PLAYERS
  • TABLE 66 BIOINFORMATICS MARKET FOR DATABASE & DATA MANAGEMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 67 CLOUD & MANAGED BIOINFORMATICS SERVICES OFFERED BY KEY MARKET PLAYERS
  • TABLE 68 BIOINFORMATICS MARKET FOR CLOUD & MANAGED BIOINFORMATICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 69 CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT SERVICES OFFERED BY KEY MARKET PLAYERS
  • TABLE 70 BIOINFORMATICS MARKET FOR CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 71 OTHER BIOINFORMATICS SERVICES OFFERED BY KEY MARKET PLAYERS
  • TABLE 72 BIOINFORMATICS MARKET FOR OTHER SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 73 BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 74 BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 75 BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 76 BIOINFORMATICS MARKET FOR SEQUENCE ANALYSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 77 BIOINFORMATICS MARKET FOR VARIANT ANALYSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 78 BIOINFORMATICS MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 79 BIOINFORMATICS MARKET FOR OTHER DATA ANALYSIS FUNCTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 80 BIOINFORMATICS MARKET FOR STRUCTURAL & FUNCTIONAL ANALYSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 81 BIOINFORMATICS MARKET FOR MULTIOMICS INTEGRATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 82 BIOINFORMATICS MARKET FOR CLINICAL INTERPRETATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 83 BIOINFORMATICS MARKET FOR DATA VISUALIZATION & REPORTING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 84 BIOINFORMATICS MARKET FOR OTHER FUNCTIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 85 BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 86 BIOINFORMATICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 87 BIOINFORMATICS MARKET FOR PRECISION MEDICINE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 88 BIOINFORMATICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 89 BIOINFORMATICS MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 90 BIOINFORMATICS MARKET FOR RESEARCH & ACADEMIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 91 BIOINFORMATICS MARKET FOR OTHER USE CASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 92 BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 93 BIOINFORMATICS MARKET FOR MEDICAL BIOTECHNOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 94 BIOINFORMATICS MARKET FOR ANIMAL BIOTECHNOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 95 BIOINFORMATICS MARKET FOR PLANT BIOTECHNOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 96 BIOINFORMATICS MARKET FOR ENVIRONMENTAL BIOTECHNOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 97 BIOINFORMATICS MARKET FOR FORENSIC BIOTECHNOLOGY, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 98 BIOINFORMATICS MARKET FOR OTHER SECTORS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 99 BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 100 BIOINFORMATICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 101 BIOINFORMATICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 102 BIOINFORMATICS MARKET FOR HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 103 BIOINFORMATICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 104 BIOINFORMATICS MARKET FOR GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 105 BIOINFORMATICS MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 106 BIOINFORMATICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 107 NORTH AMERICA: BIOINFORMATICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 NORTH AMERICA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 109 NORTH AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 110 NORTH AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 111 NORTH AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 112 NORTH AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 113 NORTH AMERICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 114 NORTH AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 115 NORTH AMERICA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 116 NORTH AMERICA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 117 NORTH AMERICA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 118 US: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 119 US: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 120 US: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 121 US: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 122 US: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 123 US: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 124 US: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 125 US: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 126 US: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 127 US: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 128 CANADA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 129 CANADA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 130 CANADA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 131 CANADA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 132 CANADA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 133 CANADA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 134 CANADA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 135 CANADA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 136 CANADA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 137 CANADA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 138 EUROPE: BIOINFORMATICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 139 EUROPE: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 140 EUROPE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 141 EUROPE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 142 EUROPE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 143 EUROPE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 144 EUROPE: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 145 EUROPE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 146 EUROPE: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 147 EUROPE: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 148 EUROPE: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 149 GERMANY: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 150 GERMANY: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 151 GERMANY: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 152 GERMANY: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 153 GERMANY: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 154 GERMANY: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 155 GERMANY: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 156 GERMANY: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 157 GERMANY: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 158 GERMANY: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 159 UK: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 160 UK: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 161 UK: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 162 UK: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 163 UK: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 164 UK: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 165 UK: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 166 UK: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 167 UK: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 168 UK: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 169 FRANCE: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 170 FRANCE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 171 FRANCE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 172 FRANCE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 173 FRANCE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 174 FRANCE: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 175 FRANCE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 176 FRANCE: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 177 FRANCE: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 178 FRANCE: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 179 ITALY: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 180 ITALY: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 181 ITALY: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 182 ITALY: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 183 ITALY: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 184 ITALY: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 185 ITALY: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 186 ITALY: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 187 ITALY: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 188 ITALY: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 189 SPAIN: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 190 SPAIN: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 191 SPAIN: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 192 SPAIN: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 193 SPAIN: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 194 SPAIN: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 195 SPAIN: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 196 SPAIN: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 197 SPAIN: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 198 SPAIN: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 199 REST OF EUROPE: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 200 REST OF EUROPE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 201 REST OF EUROPE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 202 REST OF EUROPE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 203 REST OF EUROPE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 204 REST OF EUROPE: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 205 REST OF EUROPE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 206 REST OF EUROPE: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 207 REST OF EUROPE: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 208 REST OF EUROPE: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: BIOINFORMATICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 220 CHINA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 221 CHINA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 222 CHINA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 223 CHINA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 224 CHINA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 225 CHINA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 226 CHINA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 CHINA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 228 CHINA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 229 CHINA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 230 JAPAN: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 231 JAPAN: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 232 JAPAN: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 233 JAPAN: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 234 JAPAN: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 235 JAPAN: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 236 JAPAN: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 237 JAPAN: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 238 JAPAN: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 239 JAPAN: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 240 INDIA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 241 INDIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 242 INDIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 243 INDIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 244 INDIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 245 INDIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 246 INDIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 247 INDIA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 248 INDIA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 249 INDIA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 250 AUSTRALIA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 251 AUSTRALIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 252 AUSTRALIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 253 AUSTRALIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 254 AUSTRALIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 255 AUSTRALIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 256 AUSTRALIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 257 AUSTRALIA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 258 AUSTRALIA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 259 AUSTRALIA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 260 SOUTH KOREA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 261 SOUTH KOREA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 262 SOUTH KOREA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 263 SOUTH KOREA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 264 SOUTH KOREA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 265 SOUTH KOREA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 266 SOUTH KOREA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 267 SOUTH KOREA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 268 SOUTH KOREA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 269 SOUTH KOREA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 270 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 271 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 272 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 273 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 274 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 275 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 276 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 277 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 278 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 279 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 280 LATIN AMERICA: BIOINFORMATICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 281 LATIN AMERICA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 282 LATIN AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 283 LATIN AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 284 LATIN AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 285 LATIN AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 286 LATIN AMERICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 287 LATIN AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 288 LATIN AMERICA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 289 LATIN AMERICA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 290 LATIN AMERICA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 291 BRAZIL: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 292 BRAZIL: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 293 BRAZIL: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 294 BRAZIL: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 295 BRAZIL: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 296 BRAZIL: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 297 BRAZIL: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 298 BRAZIL: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 299 BRAZIL: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 300 BRAZIL: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 301 MEXICO: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 302 MEXICO: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 303 MEXICO: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 304 MEXICO: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 305 MEXICO: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 306 MEXICO: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 307 MEXICO: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 308 MEXICO: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 309 MEXICO: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 310 MEXICO: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 311 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 312 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 313 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 314 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 315 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 316 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 317 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 318 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 319 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 320 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 321 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 322 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 323 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 324 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 325 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 326 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 327 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 328 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 329 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 330 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 331 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 332 GCC COUNTRIES: BIOINFORMATICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 333 GCC COUNTRIES: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 334 GCC COUNTRIES: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 335 GCC COUNTRIES: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 336 GCC COUNTRIES: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 337 GCC COUNTRIES: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 338 GCC COUNTRIES: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 339 GCC COUNTRIES: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 340 GCC COUNTRIES: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 341 GCC COUNTRIES: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 342 GCC COUNTRIES: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 343 SAUDI ARABIA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 344 SAUDI ARABIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 345 SAUDI ARABIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 346 SAUDI ARABIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 347 SAUDI ARABIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 348 SAUDI ARABIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 349 SAUDI ARABIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 350 SAUDI ARABIA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 351 SAUDI ARABIA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 352 SAUDI ARABIA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 353 UAE: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 354 UAE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 355 UAE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 356 UAE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 357 UAE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 358 UAE: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 359 UAE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 360 UAE: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 361 UAE: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 362 UAE: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 363 REST OF GCC: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 364 REST OF GCC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 365 REST OF GCC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 366 REST OF GCC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 367 REST OF GCC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 368 REST OF GCC: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 369 REST OF GCC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 370 REST OF GCC: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 371 REST OF GCC: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 372 REST OF GCC: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 373 SOUTH AFRICA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 374 SOUTH AFRICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 375 SOUTH AFRICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 376 SOUTH AFRICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 377 SOUTH AFRICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 378 SOUTH AFRICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 379 SOUTH AFRICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 380 SOUTH AFRICA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 381 SOUTH AFRICA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 382 SOUTH AFRICA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 383 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 384 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 385 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 386 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 387 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 388 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024-2031 (USD MILLION)
  • TABLE 389 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 390 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY USE CASE, 2024-2031 (USD MILLION)
  • TABLE 391 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY SECTOR, 2024-2031 (USD MILLION)
  • TABLE 392 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 393 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2026
  • TABLE 394 BIOINFORMATICS MARKET: DEGREE OF COMPETITION
  • TABLE 395 BIOINFORMATICS MARKET: REGION FOOTPRINT
  • TABLE 396 BIOINFORMATICS MARKET: OFFERING FOOTPRINT
  • TABLE 397 BIOINFORMATICS MARKET: FUNCTION FOOTPRINT
  • TABLE 398 BIOINFORMATICS MARKET: USE CASE FOOTPRINT
  • TABLE 399 BIOINFORMATICS MARKET: END USER FOOTPRINT
  • TABLE 400 BIOINFORMATICS MARKET: LIST OF STARTUPS/SMES
  • TABLE 401 BIOINFORMATICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 402 BIOINFORMATICS MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, 2023-2026
  • TABLE 403 BIOINFORMATICS MARKET: DEALS, 2023-2026
  • TABLE 404 BIOINFORMATICS MARKET: EXPANSIONS, 2023-2026
  • TABLE 405 BIOINFORMATICS MARKET: OTHER DEVELOPMENTS, 2023-2026
  • TABLE 406 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 407 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 408 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 409 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 410 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 411 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 412 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 413 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 414 ILLUMINA, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 415 ILLUMINA, INC.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 416 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 417 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
  • TABLE 418 QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 419 QIAGEN N.V.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 420 QIAGEN N.V.: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 421 QIAGEN N.V.: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 422 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 423 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 424 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 425 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 426 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 427 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 428 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 429 F. HOFFMANN-LA ROCHE LTD.: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 430 REVVITY, INC.: COMPANY OVERVIEW
  • TABLE 431 REVVITY, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 432 REVVITY, INC.: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 433 REVVITY, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 434 REVVITY: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 435 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 436 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED
  • TABLE 437 EUROFINS SCIENTIFIC: DEALS, JANUARY 2023-JULY 2026
  • TABLE 438 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 439 BGI GENOMICS: COMPANY OVERVIEW
  • TABLE 440 BGI GENOMICS: PRODUCTS/SERVICES OFFERED
  • TABLE 441 BGI GENOMICS: DEALS, JANUARY 2023-JULY 2026
  • TABLE 442 WATERS CORPORATION: COMPANY OVERVIEW
  • TABLE 443 WATERS CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 444 DNANEXUS, INC. COMPANY OVERVIEW
  • TABLE 445 DNANEXUS, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 446 DNANEXUS, INC.: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 447 DNANEXUS, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 448 DNANEXUS, INC.: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 449 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
  • TABLE 450 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES OFFERED
  • TABLE 451 OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2023-JULY 2026
  • TABLE 452 OXFORD NANOPORE TECHNOLOGIES PLC: EXPANSIONS, JANUARY 2023- JULY 2026
  • TABLE 453 10X GENOMICS: COMPANY OVERVIEW
  • TABLE 454 10X GENOMICS: PRODUCTS/SERVICES OFFERED
  • TABLE 455 10X GENOMICS: DEALS, JANUARY 2023-JULY 2026
  • TABLE 456 PACBIO: COMPANY OVERVIEW
  • TABLE 457 PACBIO: PRODUCTS/SERVICES OFFERED
  • TABLE 458 PACBIO: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 459 PACBIO: DEALS, JANUARY 2023-JULY 2026
  • TABLE 460 PACBIO: EXPANSIONS, JANUARY 2023-JULY 2026
  • TABLE 461 SIEMENS AG: COMPANY OVERVIEW
  • TABLE 462 SIEMENS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 463 SIEMENS AG: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 464 SIEMENS AG: DEALS, JANUARY 2023-JULY 2026
  • TABLE 465 SIEMENS AG: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 466 SOPHIA GENETICS: COMPANY OVERVIEW
  • TABLE 467 SOPHIA GENETICS: PRODUCTS/SERVICES OFFERED
  • TABLE 468 SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 469 SOPHIA GENETICS: DEALS, JANUARY 2023-JULY 2026
  • TABLE 470 SOPHIA GENETICS: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 471 EXCELRA: COMPANY OVERVIEW
  • TABLE 472 EXCELRA: PRODUCTS/SERVICES OFFERED
  • TABLE 473 EXCELRA: PRODUCT ENHANCEMENT, JANUARY 2023-JULY 2026
  • TABLE 474 EXCELRA: DEALS, JANUARY 2023-JULY 2026
  • TABLE 475 GENEWIZ (AZENTA LIFE SCIENCES): COMPANY OVERVIEW
  • TABLE 476 GENEWIZ (AZENTA LIFE SCIENCES): PRODUCTS/SERVICES OFFERED
  • TABLE 477 GENEWIZ (AZENTA LIFE SCIENCES): DEALS, JANUARY 2023-JULY 2026
  • TABLE 478 GENEWIZ (AZENTA LIFE SCIENCES): OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 479 ONTOFORCE: COMPANY OVERVIEW
  • TABLE 480 ONTOFORCE: PRODUCTS/SERVICES OFFERED
  • TABLE 481 ONTOFORCE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 482 ONTOFORCE: DEALS, JANUARY 2023-JULY 2026
  • TABLE 483 VELSERA INC.: COMPANY OVERVIEW
  • TABLE 484 VELSERA INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 485 VELSERA INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 486 SEQERA: COMPANY OVERVIEW
  • TABLE 487 SEQERA: PRODUCTS/SERVICES OFFERED
  • TABLE 488 SEQERA: PRODUCT LAUNCHES & ENHANCEMENT, JANUARY 2023-JULY 2026
  • TABLE 489 SEQERA: DEALS, JANUARY 2023-JULY 2026
  • TABLE 490 SEQERA: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 491 RISK ASSESSMENT: BIOINFORMATICS MARKET

List of Figures

  • FIGURE 1 MARKET SCENARIO
  • FIGURE 2 GLOBAL BIOINFORMATICS MARKET, 2024-2031
  • FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOINFORMATICS MARKET, 2023-2026
  • FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF BIOINFORMATICS MARKET
  • FIGURE 5 HIGH-GROWTH SEGMENTS IN BIOINFORMATICS MARKET, 2026-2031
  • FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOINFORMATICS MARKET DURING FORECAST PERIOD
  • FIGURE 7 INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
  • FIGURE 8 SOFTWARE ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
  • FIGURE 9 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 10 BIOINFORMATICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 11 GLOBAL CANCER INCIDENCE, 2008-2030
  • FIGURE 12 FDA-APPROVED PERSONALIZED MEDICINES, 2015-2024
  • FIGURE 13 BIOINFORMATICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 14 BIOINFORMATICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 15 ECOSYSTEM ANALYSIS
  • FIGURE 16 REVENUE SHIFT IN BIOINFORMATICS MARKET
  • FIGURE 17 RECENT FUNDING OF PLAYERS IN BIOINFORMATICS MARKET
  • FIGURE 18 PATENT PUBLICATION TRENDS IN BIOINFORMATICS MARKET, 2015-2026
  • FIGURE 19 JURISDICTION AND TOP APPLICANT ANALYSIS FOR BIOINFORMATICS MARKET
  • FIGURE 20 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) IN BIOINFORMATICS MARKET (JANUARY 2015-JULY 2026)
  • FIGURE 21 MARKET POTENTIAL OF GENERATIVE AI IN ENHANCING BIOINFORMATICS
  • FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
  • FIGURE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 25 NORTH AMERICA: BIOINFORMATICS MARKET SNAPSHOT
  • FIGURE 26 ASIA PACIFIC: BIOINFORMATICS MARKET SNAPSHOT
  • FIGURE 27 REVENUE ANALYSIS OF TOP LISTED/PUBLIC PLAYERS, 2021-2025 (USD MILLION)
  • FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
  • FIGURE 29 BRAND COMPARISON
  • FIGURE 30 EV/EBITDA OF KEY VENDORS
  • FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 32 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 33 BIOINFORMATICS MARKET: COMPANY FOOTPRINT
  • FIGURE 34 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 37 QIAGEN N.V.: COMPANY SNAPSHOT (2025)
  • FIGURE 38 GILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 40 REVVITY, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
  • FIGURE 42 WATERS CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 43 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025)
  • FIGURE 44 10X GENOMICS: COMPANY SNAPSHOT (2025)
  • FIGURE 45 PACBIO: COMPANY SNAPSHOT (2025)
  • FIGURE 46 SIEMENS AG: COMPANY SNAPSHOT (2025)
  • FIGURE 47 SOPHIA GENETICS: COMPANY SNAPSHOT (2025)
  • FIGURE 48 AZENTA INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 49 RESEARCH DESIGN
  • FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 51 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 52 BOTTOM-UP APPROACH
  • FIGURE 53 TOP-DOWN APPROACH
  • FIGURE 54 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF BIOINFORMATICS MARKET
  • FIGURE 55 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 56 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!